Lexaria Bioscience Corp.

Equities

LEXX

US52886N4060

Pharmaceuticals

Delayed Nasdaq 03:45:31 2024-04-16 pm EDT 5-day change 1st Jan Change
2.31 USD +16.08% Intraday chart for Lexaria Bioscience Corp. -14.44% +84.80%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study MT
Lexaria Bioscience Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
Lexaria Bioscience Corp. Receives New Patents in the Fields of Epilepsy and Anti-Viral Agents CI
Lexaria Bioscience Names Nelson Cabatuan as Finance Chief MT
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer CI
Sector Update: Health Care Stocks Retreating Late Afternoon MT
Sector Update: Health Care MT
Lexaria Bioscience to Start Diabetes, Weight Loss Animal Study; Shares Rise MT
Maxim Group Adjusts Lexaria Bioscience Price Target to $12 From $3, Maintains Buy Rating MT
Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1 CI
Lexaria Bioscience Corp. Signs Contracts to Begin Animal Study Well-A24-1 CI
Lexaria Bioscience Corp. Announces 7% Weight Loss in Animals Supports in its Next 8-Week Animal Study CI
Lexaria Bioscience Corp. Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial CI
Lexaria Bioscience Corp. Submits Investigational New Drug Application CI
Lexaria Bioscience Corp. Unveils Extensive Planned 2024 GLP-1 Study Program CI
Lexaria Bioscience Corp. Reports Earnings Results for the First Quarter Ended November 30, 2023 CI
Lexaria Bioscience Corp. Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream CI
Lexaria Bioscience Corp. Improves Delivery, Efficacy of Glp-1 Agonists Through Proprietary Drug-Delivery Platform CI
Lexaria Bioscience Corp. Announces Positive Final Results from its Recently Completed Human Pilot Study #1 for the Oral Performance of the Rybelsus(R)-Branded GLP-1 Drug Semaglutide CI
Lexaria Bioscience Set to File Investigational New Drug Application for Hypertension Trial Within 45 Days MT
Lexaria Bioscience Corp. Announces Investigational New Drug Application Filing Update CI
Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study CI
Lexaria Bioscience Corp. Reports Earnings Results for the Full Year Ended August 31, 2023 CI
Lexaria Bioscience Corp. Evaluates Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs CI
Lexaria Enters New Global Exclusive Collaboration and License Agreement with Sulfosyn CI
Chart Lexaria Bioscience Corp.
More charts
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.99 USD
Average target price
11 USD
Spread / Average Target
+452.76%
Consensus
  1. Stock Market
  2. Equities
  3. LEXX Stock
  4. News Lexaria Bioscience Corp.
  5. Lexaria Bioscience : Closes $11 Million Public Offering